How we do it

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust

Innovation

£3.9bn

R&D investment in 2017

3

significant approvals in 2017 – Shingrix, Trelegy Ellipta and Juluca

£6.7bn

new product sales in Pharmaceuticals and Vaccines in 2017

13%

Consumer Healthcare sales in 2017 from product innovations launched over the past three years

 

 

Performance

£30.2bn

total turnover in 2017

£8.6bn

adjusted operating profit in 2017

£3.4bn

free cash flow in 2017

£3.9bn

dividends paid in 2017

 

Trust

85%

of employees proud to work at GSK

£261.6m

donated in 2017 to local communities through product donations, time and cash

1st

in Access to Medicines Index all 5 times since its launch in 2008